Stock Price Quote

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE6672.0033.1 (+0.5 %)
PREV CLOSE ( ) 6638.90
OPEN PRICE ( ) 6600.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10476
TODAY'S LOW / HIGH ( )6600.30 6719.95
52 WK LOW / HIGH ( )5637.5 7077.7
NSE6655.5017 (+0.26 %)
PREV CLOSE( ) 6638.50
OPEN PRICE ( ) 6635.00
BID PRICE (QTY) 6655.50 (7)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 228572
TODAY'S LOW / HIGH( ) 6625.00 6720.00
52 WK LOW / HIGH ( )5636.5 7071.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300 / 400

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

11Jun Divis Laboratories informs about deduc
Divis Laboratories has informed that the Company has sent detailed commu..
25May Divi's Laboratories’ consolidated net
Divi's Laboratories has reported results for the fourth quarter (Q4FY26)..
31Mar Divi’s Laboratories informs about clos
Pursuant to the Company’s Code of Conduct to Regulate, Monitor and Repor..
30Jan Divis Laboratories informs about board
Divis Laboratories has informed that the meeting of the Board of Directo..
03Jan Divi's Laboratories informs about cert
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Reg..

Financials

in Millions
QTR Mar 26 ANNUAL 26
Net Profit756026070
Gross Profit 9710 34360
Operating Profit 1097039940
Net Sales 27930103880

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Torrent Pharma (BSE)
peergroup  4589.80 (2.83%)
M.Cap ( in Cr)154903.09
Wockhardt (BSE)
peergroup  1927.00 (5.14%)
M.Cap ( in Cr)31250.49
RPG Life Sciences (BSE)
peergroup  2191.90 (3.88%)
M.Cap ( in Cr)3659.84
Venus Remedies (BSE)
peergroup  1716.45 (5.00%)
M.Cap ( in Cr)2294.38
Ajanta Pharma (BSE)
peergroup  3142.70 (2.27%)
M.Cap ( in Cr)39347.23

Shareholding Pattern

NON-INSTITUTION 8.6%
PROMOTERS 51.88%
FI/BANKS/INSURANCE 4.82%
MUTUAL FUNDS/UTI 13.42%
GOVERNMENT 0%
FII 0%

About Divi's Laboratories Ltd.

Divi's Laboratories Ltd. was incorporated in the year 1990. Its today's share price is 6672. Its current market capitalisation stands at Rs 176815.35 Cr. In the latest quarter, company has reported Gross Sales of Rs. 92450 Cr and Total Income of Rs.95500 Cr. The company's management includes Sunaina Singh, Rajendra Kumar Premchand, K V Chowdary, S Ganapaty, Ramesh BV Nimmagadda, Nilima Prasad Divi, N V Ramana, S Devendra Rao, Kiran S Divi, Murali K Divi, M Satish Choudhury.

It is listed on the BSE with a BSE Code of 532488 , NSE with an NSE Symbol of DIVISLAB and ISIN of INE361B01024. It's Registered office is at 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,GachibowliHyderabad-500032, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Price Waterhouse Chartered Accountants LLP, PVRK Nageswara Rao & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.